SCHEMBL483695

SCHEMBL483695

CC(C)(C)OC(=O)N1[C@@H](c2ccc(OCc3ccccc3F)cc2)CC[C@@]1(C)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.51
SCN3A Q9NY46 8/20 0.50
SCN1A P35498 1/20 0.46
SCN4A P35499 1/20 0.46
SCN7A Q01118 1/20 0.46
SCN5A Q14524 1/20 0.46
SCN9A Q15858 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
SCN10A Q9Y5Y9 1/20 0.46
MAOB P27338 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP2C19 P33261 1/20 0.46
BTK Q06187 1/20 0.45
FFAR2 O15552 1/20 0.42
MMP1 P03956 2/20 0.42
ADAM17 P78536 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310675 0.92 KCNH2 (0.55) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL483793 0.92 KCNH2 (0.55) KCNH2SCN3ASCN1ASCN4ASCN7A
Ethane SCHEMBL483694 0.88 YAP1 (0.45) KCNH2MAOBADAM17
SCHEMBL484203 0.88 YAP1 (0.45) KCNH2MAOBADAM17
SCHEMBL483557 0.88 YAP1 (0.45) KCNH2MAOBADAM17
SCHEMBL483558 0.88 YAP1 (0.45) KCNH2MAOBADAM17
SCHEMBL483518 0.88 YAP1 (0.45) KCNH2MAOBADAM17
SCHEMBL483792 0.87 KCNH2 (0.51) KCNH2SCN3ASCN1ASCN4ASCN7A
SCHEMBL482955 0.86 KCNH2 (0.52) KCNH2SCN3APARP15PARP10
SCHEMBL484118 0.86 KCNH2 (0.52) KCNH2SCN3APARP15PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 US disclosed
EP-1934176-B1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LTD (GB) 2012-02-01 EP disclosed
EP-2117562-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LTD (GB) 2011-10-26 EP disclosed
EP-2129381-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 Glaxo Group Limited (GB) 2009-12-09 EP disclosed
EP-2117538-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) Glaxo Group Limited (GB) 2009-11-18 EP disclosed
EP-2117562-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008090114-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) GLAXO GROUP LIMITED (GB) 2008-07-31 WO disclosed
WO-2008090117-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 GLAXO GROUP LIMITED (GB) 2008-07-31 WO disclosed
WO-2008090115-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2008-07-31 WO disclosed